May 31, 2022 PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery View Article
May 23, 2022 PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis View Article
March 2, 2022 PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery View Article
November 18, 2021 PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery View Article
October 17, 2021 “In the biotech industry, the one thing that is missing more than anything else is funding” View Article
September 21, 2021 Dr. Noam Emanuel on Tackling Surgical Site Infections, a $10 Billion Healthcare System Problem View Article
September 13, 2021 PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer View Article
February 16, 2021 PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections View Article
December 22, 2020 PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program View Article
